Results 281 to 290 of about 133,761 (337)

Targeting aerobic glycolysis combats tyrosine kinase inhibitor resistance of hepatocellular carcinoma

International Journal of Cancer, Volume 158, Issue 3, Page 475-487, 1 February 2026.
Abstract Hepatocellular carcinoma (HCC) represents the predominant form of primary liver cancer and is frequently identified at a late stage, necessitating systemic therapy. However, resistance to first‐line tyrosine kinase inhibitor therapies, such as sorafenib and lenvatinib, remains a significant clinical challenge.
Longtao Zhao, Junjie Cheng, Yiming Zheng, Jing Wu, Jia Fan, Haixiang Sun, Chao Gao   +6 more
wiley   +1 more source

The Role of Exosomes as a Key Factor of Cytostatic Resistance in Cancer: Mechanisms of Action, Potential Biomarkers, and Possible Exosome-Based Therapies. [PDF]

Oncol Res
Kałużna S, Świerczewska M, Ciesiółka S, Partyka M, Nowicki M, Wojtowicz K.   +5 more
europepmc   +1 more source

Combining Correlative Cryogenic Fluorescence and Electron Microscopy and Correlative Cryogenic Super‐Resolution Fluorescence and X‐Ray Tomography—Novel Complementary 3D Cryo‐Microscopy Across Scales to Reveal Nanoparticle Internalization Into Cancer Cells

Microscopy Research and Technique, Volume 89, Issue 2, Page 260-272, February 2026.
A newly established 3D correlative cryogenic fluorescence microscopy, focused ion beam scanning electron microscopy, and soft x‐ray tomography workflow allowed for enough contrast and resolution to quantify the intracellular uptake of zirconyl‐containing inorganic–organic hybrid nanoparticles as a novel chemotherapeutic drug delivery system into ...
Pavitra Sokke Rudraiah, Louisa Herbsleb, Michaela Salakova, Henriette Gröger, Anna Maria Steyer, Frauke Alves, Claus Feldmann, Andreas Walter   +7 more
wiley   +1 more source

Bibliometric-driven research on chemoresistance in breast cancer: knowledge mapping, hotspot evolution, and emerging insights (1994-2024). [PDF]

Discov Oncol
Zhang H, Feng T, Lin J, Yahaya BH.
europepmc   +1 more source

Spatial analysis of HPV‐associated cervical intraepithelial neoplastic tissues demonstrate distinct immune signatures associated with cervical cancer progression

The Journal of Pathology, Volume 268, Issue 2, Page 200-214, February 2026.
Abstract Cervical cancer remains the fourth most common cancer affecting women worldwide, and incidences of other HPV‐related cancers continue to rise. For the development of effective prevention strategies in high‐risk patients, we aimed to better understand the roles of inflammatory pathways and the tumour microenvironment as the main driver of ...
Gianna Pavilion, Hani Vu, Zherui Xiong, Thi Viet Trinh Dang, Blake O'Brien, Michael Walsh, Andrew Causer, Janin Chandra, Quan Nguyen, Ian H Frazer   +9 more
wiley   +1 more source

High matrix stiffness triggers the YAP-OPA1-TET1/3 loop to drive chemoresistance via enhanced nuclear-mitochondrial communication. [PDF]

iScience
Wu P, Wang S, Hu Z, Zhang H, Lin Y, Li Z, Wu J, Chen Y, Chen Y, Xu Y, Li J, Guan Y.   +11 more
europepmc   +1 more source

Paeonol Inhibits Cell Growth by Inducing Ferroptosis in Human Glioma Cells

Pharmacology Research &Perspectives, Volume 14, Issue 1, February 2026.
ABSTRACT Paeonol (PAE), a phenolic phytochemical derived from traditional Chinese medicinal plants, exhibits multifaceted pharmacological properties including demonstrated antitumor efficacy against hepatic, gastric, and breast carcinomas. However, its therapeutic potential in glioma remains unexplored.
Xin Li, Xue‐Qi Liao, Wen‐Rui Chen, Tao Wu, Jin‐Xuan Li, Ling Wang, Bin‐Sheng He, Xin Qin, Jin‐Que Luo   +8 more
wiley   +1 more source

Gemcitabine-induced neutrophil extracellular traps via interleukin-8-CXCR1/2 pathway promote chemoresistance in pancreatic cancer. [PDF]

Br J Cancer
Nogi S, Kagawa S, Taniguchi A, Yagi T, Kanaya N, Kakiuchi Y, Yasui K, Fuji T, Kono Y, Kikuchi S, Takagi K, Kuroda S, Teraishi F, Tazawa H, Fujiwara T.   +14 more
europepmc   +1 more source

Identification of prokineticin‐2 as potential pharmacodynamic biomarker for overcoming doxorubicin resistance in multicellular breast cancer spheroids

British Journal of Pharmacology, Volume 183, Issue 3, Page 491-504, February 2026.
Background and purpose Despite advances in immunotherapy, doxorubicin (Dox) chemotherapy is still the irreplaceable first‐line therapy for solid tumours such as breast cancer. However, chemotherapy resistance is the major limiting factor, requiring the use of high doses of Dox to achieve the anti‐tumour actions, often leading to severe side effects ...
Martina Vincenzi, Amin Kremic, Nathalie N. Tscheiller, Po‐Yen Hsu, Michael W. Y. Chan, Roberta Lattanzi, Canan G. Nebigil   +6 more
wiley   +1 more source

Lysine demethylases 6 A and 6B as epigenetic regulators in therapeutic resistance of cancer. [PDF]

Clin Epigenetics
Yang L, Li H, Zhao Y, Qian Z, Luo G, Chen X, Yang X.   +6 more
europepmc   +1 more source